Anti-IH in myelodysplastic syndrome
Issued Date
2025-07-01
Resource Type
eISSN
23525517
Scopus ID
2-s2.0-105001714772
Journal Title
Practical Laboratory Medicine
Volume
45
Rights Holder(s)
SCOPUS
Bibliographic Citation
Practical Laboratory Medicine Vol.45 (2025)
Suggested Citation
Wongba K., Nuchnoi P., Plabplueng C., Promwong C. Anti-IH in myelodysplastic syndrome. Practical Laboratory Medicine Vol.45 (2025). doi:10.1016/j.plabm.2025.e00468 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/109472
Title
Anti-IH in myelodysplastic syndrome
Author(s)
Author's Affiliation
Corresponding Author(s)
Other Contributor(s)
Abstract
Background: Anti-IH exhibits complex specificity, strongly reacting with cells expressing both H and I antigens at cold temperatures. Its clinical significance has been increasingly recognized, particularly in patients with hematologic conditions such as myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML). Case report: We present an 83-year-old Thai female with MDS who was transfusion-dependent. She presented with severe anemia requiring an urgent transfusion. The patient was group A RhD-positive. Antibody screening and identification using column agglutination technology (CAT) showed weak polyagglutination. Auto-control and direct antiglobulin tests (DAT) were negative. Red cell typing showed absence of H antigen and presence of A1 antigen. Further testing with cord O cells revealed no agglutination, confirming the A1 blood group with anti-IH. Antibody screening and identification studies showed cold-reactivity, with weak reactivity at 37 °C and in the AHG phase. Crossmatching with two group A leukocyte-poor red cells was compatible, and transfusion was uneventful. Conclusion: This is the first reported case of anti-IH in a Thai patient. Anti-IH may complicate pre-transfusion testing and mask alloantibodies, necessitating careful interpretation and confirmatory testing to prevent transfusion-related complications.